Evercore ISI began coverage on shares of Illumina (NASDAQ:ILMN) in a research note released on Wednesday. The firm issued an outperform rating and a $250.00 price objective on the life sciences company’s stock.

Several other analysts have also issued reports on ILMN. Leerink Swann restated an outperform rating and issued a $225.00 target price (up from $207.00) on shares of Illumina in a research note on Tuesday, September 12th. Argus boosted their target price on Illumina from $205.00 to $235.00 and gave the company a buy rating in a research note on Wednesday, September 13th. Vetr upgraded Illumina from a hold rating to a buy rating and set a $217.50 target price on the stock in a research note on Tuesday, September 19th. Goldman Sachs Group restated a neutral rating and issued a $200.00 target price on shares of Illumina in a research note on Tuesday, September 26th. Finally, Piper Jaffray Companies restated an overweight rating and issued a $226.00 target price (up from $202.00) on shares of Illumina in a research note on Monday, October 9th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and fifteen have given a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus price target of $207.74.

Shares of Illumina (ILMN) opened at $228.17 on Wednesday. The stock has a market capitalization of $34,016.54, a price-to-earnings ratio of 42.73, a price-to-earnings-growth ratio of 3.19 and a beta of 0.79. The company has a debt-to-equity ratio of 0.41, a current ratio of 4.22 and a quick ratio of 3.73. Illumina has a one year low of $132.02 and a one year high of $233.54.

Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.99 by $0.12. The firm had revenue of $714.00 million for the quarter, compared to analyst estimates of $692.77 million. Illumina had a return on equity of 19.42% and a net margin of 30.34%. The business’s revenue was up 17.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.97 earnings per share. equities research analysts predict that Illumina will post 3.75 EPS for the current year.

In other news, Director Jay T. Flatley sold 20,000 shares of the company’s stock in a transaction dated Tuesday, October 10th. The stock was sold at an average price of $203.27, for a total value of $4,065,400.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Omead Ostadan sold 3,540 shares of the company’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $226.91, for a total value of $803,261.40. Following the completion of the transaction, the executive vice president now owns 26,827 shares of the company’s stock, valued at $6,087,314.57. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 158,921 shares of company stock valued at $33,810,181. 0.89% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Private Asset Management Inc. boosted its holdings in shares of Illumina by 2.2% in the 4th quarter. Private Asset Management Inc. now owns 11,072 shares of the life sciences company’s stock worth $2,419,000 after purchasing an additional 240 shares in the last quarter. Parametric Portfolio Associates LLC boosted its holdings in shares of Illumina by 41.2% in the 3rd quarter. Parametric Portfolio Associates LLC now owns 290,458 shares of the life sciences company’s stock worth $57,859,000 after purchasing an additional 84,690 shares in the last quarter. Moors & Cabot Inc. boosted its holdings in shares of Illumina by 7.1% in the 3rd quarter. Moors & Cabot Inc. now owns 7,500 shares of the life sciences company’s stock worth $1,497,000 after purchasing an additional 500 shares in the last quarter. IFM Investors Pty Ltd purchased a new position in shares of Illumina in the 3rd quarter worth about $804,000. Finally, DF Dent & Co. Inc. boosted its holdings in shares of Illumina by 4.0% in the 3rd quarter. DF Dent & Co. Inc. now owns 486,530 shares of the life sciences company’s stock worth $96,917,000 after purchasing an additional 18,741 shares in the last quarter. Hedge funds and other institutional investors own 91.60% of the company’s stock.

TRADEMARK VIOLATION WARNING: This news story was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.watchlistnews.com/evercore-isi-begins-coverage-on-illumina-ilmn/1797398.html.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with Analyst Ratings Network's FREE daily email newsletter.